Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications
Modern Pathology · 2024
DOI: 10.1016/j.modpat.2024.100557 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2024. Verfasst von Dilara Akbulut und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Laboratory of Pathology, Center for Canc…. Hauptthemen laut MEDLINE: Basic Helix-Loop-Helix Proteins, Urinary Bladder Neoplasms, Biomarkers, Tumor, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCI, National Institutes of Health.
Abstract (Originalsprache)
Small cell carcinomas (SMC) of the lung are now molecularly classified based on the expression of transcriptional regulators (NEUROD1, ASCL1, POU2F3, and YAP1) and DLL3, which has emerged as an investigational therapeutic target. PLCG2 has been shown to identify a distinct subpopulation of lung SMC with stem cell-like and prometastasis features and poor prognosis. We analyzed the expression of these novel neuroendocrine markers and their association with traditional neuroendocrine markers and patient outcomes in a cohort of bladder neuroendocrine carcinoma (NEC) consisting of 103 SMC and 19 large cell NEC (LCNEC) assembled in tissue microarrays. Coexpression patterns were assessed and integrated with detailed clinical annotation including overall (OS) and recurrence-free survival (RFS) and response to neoadjuvant/adjuvant chemotherapy. We identified 5 distinct molecular subtypes in bladder SMC based on the expression of ASCL1, NEUROD1, and POU2F3: ASCL1+/NEUROD1- (n = 33; 34%), ASCL1- /NEUROD1+ (n = 21; 21%), ASCL1+/NEUROD1+ (n = 17; 17%), POU2F3+ (n = 22, 22%), and ASCL1- /NEUROD1- /POU2F3- (n = 5, 5%). POU2F3+ tumors were mutually exclusive with those expressing ASCL1 and NEUROD1 and exhibited lower expression of traditional neuroendocrine markers. PLCG2 expression was noted in 33 tumors (32%) and was highly correlated with POU2F3 expression (P < .001). DLL3 expression was high in both SMC (n = 72, 82%) and LCNEC (n = 11, 85%). YAP1 expression was enriched in nonneuroendocrine components and negatively correlated with all neuroendocrine markers. In patients without metastatic disease who underwent radical cystectomy, PLCG2+ or POU2F3+ tumors had shorter RFS and OS (P < .05), but their expression was not associated with metastasis status or response to neoadjuvant/adjuvant chemotherapy. In conclusion, the NEC of the bladder can be divided into distinct molecular subtypes based on the expression of ASCL1, NEUROD1, and POU2F3. POU2F3-expressing tumors represent an ASCL1/NEUROD1-negative subset of bladder NEC characterized by lower expression of traditional neuroendocrine markers. Marker expression patterns were similar in SMC and LCNEC. Expression of PLCG2 and POU2F3 was associated with shorter RFS and OS. DLL3 was expressed at high levels in both SMC and LCNEC of the bladder, nominating it as a potential therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health,…
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Pathology and Laboratory Medicine, Henry Ford Hospital, Detroit, Michigan.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Förderung
- NCI NIH HHS
- NCI
- National Institutes of Health
- Cycle for Survival
Zitieren
APA
Akbulut, D., Whiting, K., Teo, M. Y., Tallman, J. E., Ozcan, G. G., Basar, M., Jia, L., Rammal, R., Chen, J. F., Sarungbam, J., Chen, Y. B., Gopalan, A., Fine, S. W., Tickoo, S. K., Mehra, R., Baine, M., Bochner, B. H., Pietzak, E. J., Bajorin, D. F., …, & Al-Ahmadie, H. (2024). Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications. Modern Pathology. https://doi.org/10.1016/j.modpat.2024.100557
Vancouver
Akbulut D, Whiting K, Teo MY, Tallman JE, Ozcan GG, Basar M, et al. Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications. Modern Pathology. 2024. doi:10.1016/j.modpat.2024.100557
BibTeX
@article{Akbulut2024,
author = {Akbulut, Dilara and Whiting, Karissa and Teo, Min-Yuen and Tallman, Jacob E and Ozcan, Gamze Gokturk and Basar, Merve and Jia, Liwei and Rammal, Rayan and Chen, Jie-Fu and Sarungbam, Judy and Chen, Ying-Bei and Gopalan, Anuradha and Fine, Samson W and Tickoo, Satish K and Mehra, Rohit and Baine, Marina and Bochner, Bernard H and Pietzak, Eugene J and Bajorin, Dean F and Rosenberg, Jonathan E and Iyer, Gopa and Solit, David B and Reuter, Victor E and Rekhtman, Natasha and Ostrovnaya, Irina and Al-Ahmadie, Hikmat},
title = {Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications},
journal = {Modern Pathology},
year = {2024},
doi = {10.1016/j.modpat.2024.100557}
}
EUVIMED